Cardiac arrhythmias are disorders that can occur in the regularity of the heart rhythm. They may manifest as an excessively fast or slow heart rate, a completely irregular rhythm, or brief pauses in the rhythmic contraction of the heart. Arrhythmias encompass a broad spectrum of disorders and can, depending on the case, range from completely benign to exceptionally life-threatening. Cardiologists specializing in the interpretation, diagnosis, and management of cardiac arrhythmias are called rhythmologists or electrophysiologists, and the corresponding subspecialty of cardiology is known as cardiac electrophysiology.
The Electrical System of the Heart
To understand how arrhythmias occur, basic knowledge of the heart’s electrical or conduction system is helpful. With every heartbeat, the heart muscle, the myocardium, contracts to pump blood, thereby ensuring the blood supply to all organs and tissues of the body. Myocardial contraction is triggered by an electrical impulse generated in the sinoatrial (SA) node, an area also referred to as the natural pacemaker, located in the right atrium of the heart.
This electrical signal follows a specific and highly programmed pathway, initially stimulating the heart’s atria (right and left), forcing them to contract and propel blood into the ventricles (right and left). The impulse then passes through the atrioventricular (AV) node located between the atria and the ventricles. In the AV node, the passage of the impulse undergoes a brief delay (0.12–0.20 seconds), which serves to protect the ventricles from a cascading descent of a multitude of impulses from the atria.
Subsequently, the electrical signal passes rapidly through the bundle of His and then propagates via two branches, the right and left bundle branches, into the respective cardiac ventricles to trigger their contraction, which ejects blood to peripheral organs. The normal heart rhythm that follows this sequence is also called sinus rhythm, as this rhythmic orchestration always originates from the SA node.
The Discovery of the Electrocardiogram
The first fundamental step in medical history toward understanding arrhythmias occurred with the discovery of the electrocardiogram, thanks to the ingenuity of the Dutch physician and physiologist Willem Einthoven. Since the beginning of the last century, Einthoven knew that the electrical activity of the heart propagates to the skin surface because the human body is a good conductor of electricity. In 1903, with the aid of a specialized galvanometer, he was able to record this electrical activity, discovering the familiar electrocardiogram. For this breakthrough discovery, he was awarded the Nobel Prize in Physiology or Medicine in 1924.
How Arrhythmias Arise
Normally, the heart operates at 60 to 100 beats per minute. The heart rate can vary depending on the metabolic demands of the body, but this occurs in a smooth, gradual manner. Frequently, this orderly function is disrupted by arrhythmias, which cause the heart to beat either more slowly, termed bradycardias, or faster, termed tachycardias. At other times, the rhythm becomes entirely irregular, such as in atrial fibrillation, or presents with contractions interposed within the normal rhythm, causing minor, momentary pauses, referred to as premature beats or ectopy.
Tachycardias arise via various mechanisms. One such mechanism involves re-entrant circuits, where the electrical impulse rapidly follows a circular pathway around an anatomically defined region, and the resulting rapid stimulation overrides the normal sinus rhythm, causing the heart to operate at an unusually high rate. Another mechanism is abnormal automaticity, where stimulation is triggered by the ultra-rapid discharge of a specific focal point within the atria or ventricles of the heart.
Symptoms Caused by Arrhythmias
Occasionally, arrhythmias may remain asymptomatic and are discovered incidentally during a routine medical examination. Usually, however, arrhythmias provoke palpitations. The patient may perceive momentary pauses in the heart rhythm, remarkably forceful individual beats, or bursts of tachycardia lasting a few seconds that recur periodically.
In cases of paroxysmal tachycardias, whether supraventricular or ventricular, patients suddenly experience a profound tachycardia that is frequently intolerable, lasting from a few minutes to several hours or even days, and invariably terminates abruptly—either spontaneously, through vagal maneuvers (Valsalva maneuver, carotid sinus massage, coughing, etc.), or ultimately, via pharmacological intervention, typically intravenous. Sometimes, arrhythmias are not perceived as an anomalous heartbeat per se, but instead manifest as generalized weakness, dizziness, easy fatigability, dyspnea, or chest discomfort.
If the tachycardia features an exceptionally high rate (especially in patients with severe structural heart disease) or if the ventricles cease to contract due to cardiac arrest or advanced atrioventricular block, cerebral perfusion decreases precipitously, potentially resulting in syncope (loss of consciousness). If the arrhythmic disorder self-terminates rapidly, consciousness is restored. Conversely, if the arrhythmia responsible for the syncope does not resolve, it can lead to sudden cardiac death. Fatality can only be averted if immediate medical intervention is administered within a window of a few minutes.
Types of Arrhythmias
Arrhythmias are classified into tachycardias or tachyarrhythmias, when the heart rate exceeds 100 beats per minute, and bradycardias or bradyarrhythmias, when the heart rate falls below 60 beats per minute. Tachycardias are further categorized based on whether their origin lies within the atria or the ventricles of the heart, termed supraventricular or ventricular, respectively.
Supraventricular Arrhythmias
Supraventricular arrhythmias encompass the following types:
- Premature Atrial Contractions (PACs): These are isolated contractions originating from the atria that transiently, and potentially repetitively, interpose within the normal sinus rhythm. If a premature contraction occurs after every normal beat, the phenomenon is termed atrial bigeminy, whereas if it occurs after two consecutive normal beats, it is termed trigeminy. Premature beats are exceedingly common and may be felt as minor skips or thumping sensations.
- Atrioventricular Nodal Re-entrant Tachycardia (AVNRT): This is a tachycardia caused by a re-entrant circuit located within or immediately adjacent to the AV node. This paroxysmal tachycardia occurs in individuals with structurally normal hearts and exhibits a slight female predominance. It begins abruptly without an obvious precipitating factor, typically featuring a rate of 130–200 beats per minute, and its termination may require intravenous medical intervention. It can manifest at any age, but most frequently arises between 30–50 years of age.
- Tachycardias involving an accessory pathway (such as Wolff-Parkinson-White syndrome): In these tachycardias, the causative substrate is an accessory pathway. Normally, the sole electrical communication between atria and ventricles is the AV node and the bundle of His. However, some individuals, who otherwise possess entirely normal hearts, have an additional electrical connection between the atria and ventricles, acting like an extra wire. This accessory pathway, which can usually be diagnosed on a standard electrocardiogram, lacks the decremental conduction capabilities of the AV node; instead, it conducts impulses at high velocity. Consequently, re-entrant electrical circuits are formed, precipitating episodes of tachycardia that often necessitate specialized maneuvers or emergency hospital intervention to terminate. This clinical entity is termed Wolff-Parkinson-White (WPW) syndrome, named after cardiologists Louis Wolff, John Parkinson, and Paul Dudley White, who fully described it in 1930. If atrial fibrillation occurs in these individuals and the accessory pathway possesses high-rate anterograde conduction, the rapid impulses from the atria can be transmitted directly to the ventricles, triggering ventricular fibrillation, which is highly fatal. Fortunately, such cases are rare, and today we can definitively eliminate these pathways via catheter ablation.
- Atrial Fibrillation (AF): This is the most common sustained arrhythmia, affecting 1–2% of the general population. It can present as brief, self-terminating episodes (paroxysmal AF), persist for prolonged periods requiring medical intervention to terminate (persistent AF), or remain permanently established (permanent/chronic AF). The incidence of AF increases significantly in the elderly, though it frequently presents in younger individuals. It typically occurs in patients with underlying cardiac disease or predisposing cardiovascular risk factors, but can also arise in individuals with structurally normal hearts. Atrial fibrillation is characterized by rapid, chaotic, and uncoordinated atrial activation. This results in the transmission of multiple, irregular impulses to the ventricles, causing a highly irregular ventricular response. Due to the disorganized atrial contraction, blood flow stales and undergoes stasis within the atria, particularly the left atrial appendage. This promotes thrombus formation; these clots can embolize into the systemic circulation, frequently occluding a cerebral artery and causing an acute ischemic stroke. Patients with AF carry a five-fold increased risk of stroke. Furthermore, chronic rapid AF induces tachycardia-mediated cardiomyopathy and heart failure, a state where the heart cannot sustain adequate cardiac output to meet peripheral tissue demands. Fortunately, these risks can be markedly mitigated with appropriate monitoring and therapeutic management.
- Atrial Flutter: This is an arrhythmia closely related to atrial fibrillation, with the distinction that electrical activity in the atria is not completely chaotic with multiple circuits, but is instead confined to one or two macro-re-entrant circuits, causing the atria to depolarize at regular rates of 240–300 beats per minute. The most common form of atrial flutter depends on a circuit located in the right atrium (cavotricuspid isthmus-dependent), which can be easily cured today via catheter ablation.
- Atrial Tachycardia: This is an arrhythmia originating from a single focal origin that discharges at a rapid rate, situated at a specific location within either the right or left atrium.
Ventricular Arrhythmias
Ventricular arrhythmias are classified into the following types:
- Premature Ventricular Contractions (PVCs): These are ectopic beats originating from one or more foci within the ventricles. They can occur frequently and manifest in patterns of bigeminy or trigeminy. Two consecutive PVCs are termed a ventricular couplet, whereas longer non-sustained runs are classified as non-sustained ventricular tachycardia (NSVT). PVCs always warrant careful evaluation, as they can indicate underlying structural heart disease or, in patients with established cardiac disease, serve as a warning sign for future malignant arrhythmic events.
- Ventricular Tachycardia (VT): This is a rapid rhythm originating from the ventricles, causing them to contract at rates that can reach up to 250 beats per minute. This ultra-rapid rate prevents adequate ventricular filling during diastole, precipitously reducing cardiac output to the periphery. In patients with severe heart failure whose cardiac output is already compromised, the onset of VT can be immediately fatal. Ventricular tachycardias occur predominantly in patients with structural heart disease, such as a prior myocardial infarction, dilated cardiomyopathy, or other forms of cardiomyopathy. Less frequently, they arise in patients without apparent structural heart disease, termed idiopathic VT, which carries a much more favorable prognosis. Conversely, when VT occurs in the presence of structural heart disease, evaluation for an implantable cardioverter-defibrillator (ICD) is mandatory.
- Ventricular Fibrillation (VF): Ventricular fibrillation is the most lethal arrhythmia, causing complete desynchronization of ventricular contraction, rendering the heart unable to pump blood. Without immediate electrical cardioversion (defibrillation/shock), it results in death within minutes. VF can occur during the acute phase of a myocardial infarction, unpredictably in patients with structural heart disease, or in individuals with genetically determined channelopathies predisposing to ventricular arrhythmias, such as Long QT syndrome and Brugada syndrome.
Bradyarrhythmias
Bradyarrhythmias are clinical conditions characterized by a pathologically low heart rate. Sinus bradycardia can, of course, be entirely physiological, such as in well-conditioned athletes or during sleep. Pathological cases are caused by abnormalities in impulse generation at the SA node or impulse conduction through the specialized conduction system. Bradyarrhythmias are classified as follows:
- Sinus Node Dysfunction (Sick Sinus Syndrome): This condition is characterized by sinus node failure; when accompanied by symptoms such as weakness, dizziness, or syncope, it is termed Sick Sinus Syndrome. Due to cellular degeneration typically associated with aging, the SA node fails to generate impulses at an appropriate frequency. Consequently, the heart may operate at a slow resting rate (e.g., 40 bpm) with an inadequate chronotropic response during exertion. Furthermore, spontaneous sinus pauses or arrests may occur, which can cause dizziness or syncope. Additionally, the loss of normal sinus dominance can lead to atrial electrical instability, frequently precipitating atrial fibrillation (tachy-brady syndrome). Symptomatic sinus node dysfunction necessitates the implantation of a permanent pacemaker. It is critical to exclude extrinsic pharmacological causes, such as beta-blockers, calcium channel blockers, or other antiarrhythmic agents, as well as ophthalmic drops used for glaucoma, which can depress sinus node function. Such medications should be discontinued unless medically indispensable, in which case pacemaker implantation becomes mandatory.
- Atrioventricular (AV) Block: Once the electrical impulse reaches the AV node, it may encounter conduction delays or blockages along its remaining path. AV block is classified into:
a) First-degree AV block: characterized simply by a prolongation of conduction from the atria to the ventricles (PR interval prolongation).
b) Second-degree AV block: characterized by intermittent failure of atrial impulses to conduct to the ventricles.
c) Third-degree (Complete) AV block: characterized by a total failure of AV conduction, where no atrial impulses reach the ventricles. Ventricular activation is maintained solely by an ectopic escape rhythm, which functions at an exceptionally low frequency (e.g., 30 bpm). AV block is typically caused by idiopathic fibrosis or degeneration of the specialized conduction system, occurring predominantly in older individuals. As with sinus node depression, potential pharmacological exacerbations must be evaluated. If no reversible causes are identified and the AV block compromises hemodynamic stability, permanent pacemaker implantation is indicated.
Which Arrhythmias Warrant Serious Concern
Arrhythmias occurring in individuals without structural heart disease may be highly symptomatic and distressing, yet they generally carry a benign prognosis, where management focuses on symptom relief and paroxysm prevention. However, certain scenarios warrant high concern even in the absence of structural defects. The presence of syncope, highly malignant morphologies (e.g., polymorphic VT), or underlying genetic substrates such as Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT) significantly elevate the risk of sudden cardiac death, necessitating rigorous diagnostic investigation and specialized therapeutic decision-making.
When arrhythmias present in patients with structural heart disease—particularly ventricular arrhythmias or atrial fibrillation—they require meticulous attention, as they often serve as markers of poor prognosis. These cases mandate an exhaustive evaluation for underlying etiologies followed by comprehensive therapeutic measures to mitigate future risk.
In atrial fibrillation, a primary source of concern is the risk of thromboembolic stroke. However, stroke risk is not uniform across all AF patients. The risk escalates in the presence of comorbidities such as heart failure, arterial hypertension, advanced age, diabetes mellitus, and a prior thromboembolic history. To quantify this risk, the CHA2DS2-VASc scoring system is universally utilized across clinical practice.
In all instances, the evaluation and management of patients with cardiac arrhythmias demand specialized electrophysiological expertise, as therapeutic decisions can critically alter patient outcomes. Consequently, complex cases should be managed at specialized arrhythmia centers by clinicians proficient in contemporary diagnostic and interventional modalities.
How Diagnosis is Established
Depending on the clinical presentation, diagnosis involves both non-invasive modalities (electrocardiogram, ambulatory Holter monitoring, exercise stress testing, echocardiography, and advanced cardiac imaging) and minimally invasive or implantable diagnostic methods (insertable loop recorders, electrophysiology studies).
- Electrocardiogram (ECG): The standard 12-lead ECG remains the cornerstone of arrhythmia diagnosis. In most instances, a definitive diagnosis is established directly from the ECG trace. For transient, paroxysmal arrhythmias, it is imperative to obtain an ECG recording during the symptomatic episode, as a post-episode trace during sinus rhythm may reveal no pathological findings.
- Ambulatory ECG Holter Monitoring: Unlike a standard ECG, which captures cardiac rhythm for only a few seconds, an ECG Holter monitor is a portable device equipped with memory and electrodes that records the continuous ECG waveform over a 24- to 48-hour period. This must be distinguished from an ambulatory blood pressure monitor, which records blood pressure at regular intervals rather than cardiac rhythm. Analysis of Holter recordings allows the determination of arrhythmia presence, specific morphology, duration, and correlation with patient symptoms. Occasionally, a 24-hour Holter monitor may detect subclinical abnormalities, such as brief asymptomatic episodes of AV block. When correlated with a clinical history of syncope, these findings can definitively confirm the underlying etiology.
- Smartwatches and Wearables: In contemporary clinical practice, smartwatches capable of recording a single-lead ECG or detecting irregular rhythms via photoplethysmography (PPG) have emerged as invaluable diagnostic adjuncts. They empower patients to capture paroxysmal arrhythmic events in real-time during daily activities as symptoms occur, providing the treating physician with critical documentation that frequently eludes conventional ambulatory Holter monitoring.
- Exercise Stress Testing: Utilized to elicit arrhythmias that are unmasked by physical exertion, as well as to evaluate for underlying coronary artery disease that may serve as an arrhythmic trigger.
- Echocardiography: Cardiac ultrasound (transthoracic echocardiography/Doppler) provides a comprehensive assessment of cardiac structure and function, ruling out myocardial or valvular pathologies that could act as an arrhythmic substrate.
- Insertable Loop Recorder (Implantable Holter): When a serious rhythm disorder is suspected as the cause of recurrent syncope but remains undetected by conventional modalities, a microscopic continuous loop recording device can be implanted subcutaneously. This device can be interrogated externally using a specialized programmer to retrieve stored data on rhythm disturbances, guiding definitive therapeutic decisions.
- Electrophysiology Study (EPS): A minimally invasive interventional procedure performed under local anesthesia via percutaneous access through the femoral veins. Specialized diagnostic catheters (thin, flexible wires) are advanced into the cardiac chambers and positioned at specific anatomical sites, including the right atrium, the right ventricle, the His bundle region, and within the coronary sinus. These catheters interface with a recording system to map local electrical activity, enabling detailed evaluation of the sinus node and specialized conduction pathways. In patients with unexplained syncope, pathological findings can confirm the indication for a permanent pacemaker. Furthermore, programmed electrical stimulation can be delivered to induce tachycardias, clarifying their exact mechanism and site of origin to guide subsequent targeted therapy. In specific scenarios, the induction of malignant ventricular tachyarrhythmias guides the indication for implantable cardioverter-defibrillator therapy. Electrophysiology studies are performed in specialized hospital laboratories and typically require a single day of hospitalization.
Therapeutic Management of Arrhythmias
The therapeutic strategy depends entirely on the specific type, severity, and risk profile of the arrhythmia. In benign, well-tolerated cases, no intervention may be required. Management options encompass pharmacological therapy, electrical cardioversion, and interventional modalities such as catheter ablation and device implantation (pacemakers and defibrillators).
- Pharmacological Therapy: Various classes of antiarrhythmic drugs are utilized. These agents are administered to terminate an active arrhythmia, restore sinus rhythm, or prevent recurrence. Additionally, rate-control medications are used to slow the ventricular response during tachyarrhythmias. Finally, oral anticoagulants are indicated in disorders like atrial fibrillation for stroke prevention. In less dangerous supraventricular tachycardias, antiarrhythmic drugs can be effective; however, they merely suppress the arrhythmia rather than providing a definitive cure. Consequently, long-term administration is required, making the manifestation of adverse drug effects inevitable. For example, amiodarone, one of our most effective antiarrhythmic agents, causes significant long-term toxicities affecting the thyroid gland, hepatic parenchyma, pulmonary tissue, and other organ systems. In recent years, data from numerous clinical trials and meta-analyses have led to a re-evaluation of the role of antiarrhythmic drugs. It has become clear that their efficacy in preventing arrhythmia recurrence is relatively modest, and in the setting of malignant, life-threatening arrhythmias, they can be entirely ineffective or even deleterious. Occasionally, these agents themselves provoke highly dangerous arrhythmias due to their proarrhythmic properties. Nonetheless, active research continues toward the development of safer, more effective molecules. In the early 2010s, the introduction of dronedarone for atrial fibrillation initially offered promise, but it subsequently demonstrated adverse outcomes, including increased mortality in specific patient subsets in the PALLAS clinical trial. Conversely, immense progress in managing underlying structural heart diseases has shown that the appropriate use of beta-blockers, antihypertensives, lipid-lowering agents, and other guideline-directed medical therapies plays a critical role in preventing sudden cardiac death by optimizing the arrhythmic substrate.
- Electrical Cardioversion: This is a procedure whereby a synchronized electrical shock is delivered across the chest wall via an external defibrillator to terminate a tachyarrhythmia and restore sinus rhythm. Although it may seem daunting to patients, it is a brief, painless procedure performed under conscious sedation. While highly effective at terminating an arrhythmia, electrical cardioversion does not prevent future recurrences.
- Catheter Ablation: Performed as an extension of the electrophysiology study, catheter ablation utilizes specialized interventional catheters advanced into the heart chambers via venous or arterial access (most commonly the femoral vessels). These steerable catheters are manipulated with high precision to map electrical signals focal point by focal point, identifying the critical substrates responsible for the arrhythmia. Advanced recording systems and three-dimensional electroanatomical mapping systems provide detailed anatomical and electrical reconstructions of the heart chambers, enhancing interventional accuracy. Ablation catheters deliver energy—most commonly radiofrequency alternating current—to create microscopic, localized lesions that destroy the arrhythmogenic tissue. Catheter ablation has become a first-line therapeutic option for several tachycardias (such as AVNRT, accessory pathway-mediated tachycardias, atrial flutter, idiopathic VT, and frequent symptomatic PVCs) before antiarrhythmic drugs are attempted. This paradigm shift is driven by the fact that ablation offers a definitive cure with high success rates exceeding 95% in these specific substrates, combined with an exceptional safety profile and minimal complications in experienced hands.
- Atrial Fibrillation Ablation: In atrial fibrillation specifically, catheter ablation is utilized with increasing frequency. Over the past decade, numerous clinical trials have demonstrated that catheter ablation is significantly superior to antiarrhythmic drug therapy in preventing AF recurrences, providing robust symptom relief and improving patient quality of life. The success rates for pulmonary vein isolation are approximately 70–80% for paroxysmal AF and are lower for persistent AF, sometimes requiring repeat procedures to achieve durable sinus rhythm. The procedure is performed in the left atrium and entails the electrical isolation of the pulmonary veins, where the primary triggering foci reside. Catheter ablation is strictly indicated for symptomatic patients with recurrent episodes; it is not recommended for asymptomatic patients with permanent AF and a dilated left atrium whose ventricular rate is adequately controlled.
In the management of atrial fibrillation, alongside traditional thermal modalities (radiofrequency ablation or cryoballoon ablation), pulsed field ablation (PFA) has emerged as a revolutionary technology. This modality utilizes ultra-rapid, high-voltage electrical fields to induce irreversible electroporation exclusively within the sarcolemma of cardiomyocytes. Because myocardial tissue possesses a lower threshold for electroporation compared to adjacent structures, PFA minimizes the risk of collateral thermal injury to sensitive neighboring organs, such as the esophagus or the phrenic nerve, thereby providing unparalleled procedural safety and speed during pulmonary vein isolation.
- Ventricular Tachycardia Ablation: Furthermore, catheter ablation of ventricular tachycardia in patients with structural heart disease represents a rapidly advancing field. Advanced mapping systems allow targeted intervention within the complex scar-related electrophysiological substrate of high-risk patients experiencing recurrent VT. These patients typically have an implanted ICD, and recurrent episodes can precipitate frequent device shocks, a life-threatening state known as an electrical storm. A major recent technical milestone is percutaneous epicardial ablation, which allows access to the external surface of the heart without surgical thoracotomy, providing access to arrhythmogenic substrates that are inaccessible via a conventional endocardial approach.
Pacemakers
Permanent cardiac pacemakers are implanted under local anesthesia via a small incision below the clavicle when bradyarrhythmias or sinus pauses compromise hemodynamic stability. The patient is typically discharged the following day and can resume full daily activities within a few days. Routine device surveillance is performed externally via a specialized programmer on a bi-annual or annual basis.
A major milestone in bradycardia therapeutics is the development of leadless pacemakers. These are self-contained, microscopic devices (approximating the size of a large capsule) that are delivered percutaneously via the femoral vein and anchored directly into the endocardium of the right ventricle. By eliminating both the subcutaneous generator pocket below the clavicle and transvenous leads, this technology entirely avoids long-term lead- and pocket-related complications, such as lead fracture, insulation failure, venous thrombosis, and systemic endovascular infections.
Conduction system pacing (such as His-bundle pacing or left bundle branch area pacing) is increasingly replacing conventional right ventricular apical pacing. Rather than stimulating a random myocardial site and inducing dyssynchronous ventricular activation, the pacing lead is deployed directly into the specialized intrinsic conduction pathways. Consequently, the electrical impulse propagates along the physiological network, maintaining synchronous ventricular contraction, preserving left ventricular function, and preventing pacing-induced cardiomyopathy over long-term follow-up.
Implantable Cardioverter-Defibrillators (ICDs)
ICDs are implanted in patients who have survived a malignant ventricular tachyarrhythmia (secondary prevention) or those with structural heart disease and severe left ventricular dysfunction who carry a high risk of sudden cardiac death (primary prevention). The implantation technique, recovery, and follow-up follow a similar workflow to permanent pacemakers.
To circumvent the long-term risks associated with indwelling transvenous leads, subcutaneous and extravascular defibrillators were developed. In the subcutaneous system (S-ICD), both the generator and the defibrillation lead are positioned entirely subcutaneously outside the thoracic rib cage, avoiding any contact with the heart or the vascular system. Building upon this paradigm, contemporary electrophysiology has introduced the extravascular ICD (EV-ICD). This alternative system utilizes a lead placed substernally—directly beneath the sternum but entirely outside the heart chambers and blood vessels. By positioning the lead closer to the myocardium, the EV-ICD can deliver effective defibrillation shocks at significantly lower energy levels compared to an S-ICD, while uniquely providing ventricular pause-prevention pacing and anti-tachycardia pacing (ATP) to terminate ventricular tachycardia without the need for a shock. Both modalities represent ideal therapeutic choices for young patients, individuals with venous occlusions, or those at high risk for systemic endovascular infections.
Cardiac Resynchronization Therapy (CRT)
In specific phenotypes of heart failure characterized by ventricular dyssynchrony (e.g., left bundle branch block), a specialized biventricular device is utilized. In addition to standard right atrial and right ventricular leads, a third lead is advanced via the coronary sinus to pace the epicardial surface of the left ventricle. Simultaneous biventricular pacing restores mechanical synchronously, markedly optimizing cardiac output, reversing ventricular remodeling, and significantly improving both functional class and overall survival in selected heart failure populations.